Gastroenterology

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The approval indicates linaclotide for pediatric patients ≥ 2 years of age with functional constipation, expanding its previous use in patients ≥ 6 years of age.

The FDA approved Abbreviated New Drug Applications from Lupin Pharmaceuticals for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials.

Catch up on 5 notable studies and trial updates from DDW 2026!

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Fukami, MD, discusses how first-line ESD may offer both survival and cost advantages over esophagectomy for EEC in the United States.

Early data suggest varenicline may improve abdominal pain, bloating, and bowel symptoms in patients with IBS.

Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.

Dellon explains phase 4 REMODEL trial data showing dupilumab’s impact on esophageal distensibility and the underlying remodeling process in eosinophilic esophagitis.

ICI colitis linked to high rehospitalization, ICU use, and mortality even after therapy discontinuation.

Despite a growing armamentarium of approved IBD therapies, outcomes remain suboptimal. Rubin explains how earlier treatment and smarter optimization can close the gap.

Laurent Peyrin-Biroulet, MD, PhD, breaks down FUZION data demonstrating meaningful fistula healing with guselkumab in Crohn’s disease patients with perianal disease.

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.

The phase 3 FUZION trial found guselkumab achieved increased fistula remission rates than placebo in perianal fistulizing Crohn's disease.